Table 3.
Relationship between the use of antipyretics and antibody response.
| After Dose 1 | Antipyretic Use | p-Value | ||
|---|---|---|---|---|
| No | Yes | |||
| Anti-S IgG (U/mL) | T1 (N = 177) | 176.13 (148.56–208.82) | 179.38 (153.93–209.03) | 0.877 |
| T2 (N = 171) | 3962.57 (3560.72–4409.77) | 4748.31 (4269.28–5281.08) | 0.022 | |
| ND50 | T1 (N = 100) | 411.50 (311.06–544.38) | 531.72 (405.05–698.02) | 0.206 |
| T2 (N = 100) | 2498.72 (2028.41–3078.08) | 3114.46 (2584.41–3753.21) | 0.124 | |
| After dose 2 | ||||
| Anti-S IgG (U/mL) | T2 (N = 171) | 3234.86 (2427.75–4310.29) | 4552.66 (4206.72–4927.06) | 0.010 |
| ND50 | T2 (N = 100) | 2611.77 (1803.82–3781.61) | 2867.83 (2476.01–3321.66) | 0.753 |
| After either dose | ||||
| Anti-S IgG (U/mL) | T2 (N = 171) | 2932.21 (2063.26–4167.13) | 4547.28 (4207.95–4913.97) | 0.004 |
| ND50 | T2 (N = 100) | 2611.77 (1803.82–3781.61) | 2867.83 (2476.01–3321.66) | 0.753 |
Data are presented as geometric mean titers (95% confidence interval). IgG, immunoglobulin G; ND50, median neutralizing titer.